Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 436856, 4 pages
http://dx.doi.org/10.4061/2011/436856
Case Report

Biopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity

1Division of Nephrology, Northwestern Memorial Hospital, Chicago, IL 60611, USA
2Department of Pharmacy Practice, College of Pharmacy, Midwestern University Chicago, Downers Grove, IL 60515, USA
3Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL 60611, USA

Received 28 February 2011; Accepted 26 April 2011

Academic Editor: Franca Anglani

Copyright © 2011 Farheen Shah-Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Vance-Bryan, D. R. P. Guay, S. S. Gilliland, K. A. Rodvold, and J. C. Rotschafer, “Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 3, pp. 436–440, 1993. View at Google Scholar · View at Scopus
  2. M. E. Winter, Basic Clinical Pharmacokinetics, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 4th edition, 2003.
  3. D. T. Bearden and K. A. Rodvold, “Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics,” Clinical Pharmacokinetics, vol. 38, no. 5, pp. 415–426, 2000. View at Google Scholar · View at Scopus
  4. M. Rybak, B. Lomaestro, J. C. Rotschafer et al., “Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,” American Journal of Health-System Pharmacy, vol. 66, no. 1, pp. 82–98, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. B. F. Farber and R. C. Moellering Jr., “Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981,” Antimicrobial Agents and Chemotherapy, vol. 23, no. 1, pp. 138–141, 1983. View at Google Scholar
  6. D. W. Woodley and W. H. Hall, “The treatment of severe staphylococcal infections with vancomycin,” Annals of Internal Medicine, vol. 55, pp. 235–249, 1961. View at Google Scholar
  7. G. R. Bailie and D. Neal, “Vancomycin ototoxicity and nephrotoxicity. A review,” Medical Toxicology and Adverse Drug Experience, vol. 3, no. 5, pp. 376–386, 1988. View at Google Scholar
  8. D. P. Levine, “Vancomycin: a history,” Clinical Infectious Diseases, vol. 42, supplement 1, pp. S5–S12, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. M. B. Goetz and J. Sayers, “Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination,” Journal of Antimicrobial Chemotherapy, vol. 32, no. 2, pp. 325–334, 1993. View at Google Scholar
  10. M. J. Rybak, B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano, “Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 7, pp. 1549–1555, 1999. View at Google Scholar
  11. M. N. Jeffres, W. Isakow, J. A. Doherty, S. T. Micek, and M. H. Kollef, “A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia,” Clinical Therapeutics, vol. 29, no. 6, pp. 1107–1115, 2007. View at Publisher · View at Google Scholar · View at PubMed
  12. L. S. Elting, E. B. Rubenstein, D. Kurtin et al., “Mississippi mud in the 1990s: risks and outcomes of vancomycin- associated toxicity in general oncology practice,” Cancer, vol. 83, no. 12, pp. 2597–2607, 1998. View at Publisher · View at Google Scholar
  13. T. P. Lodise, B. Lomaestro, J. Graves, and G. L. Drusano, “Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1330–1336, 2008. View at Publisher · View at Google Scholar · View at PubMed
  14. L. K. Hidayat, D. I. Hsu, R. Quist, K. A. Shriner, and A. Wong-Beringer, “High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2138–2144, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. T. P. Lodise, N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano, “Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients,” Clinical Infectious Diseases, vol. 49, no. 4, pp. 507–514, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. H. A. Kirst, D. G. Thompson, and T. I. Nicas, “Historical yearly usage of vancomycin,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 5, pp. 1303–1304, 1998. View at Google Scholar
  17. E. O. Mason, L. B. Lamberth, W. A. Hammerman, K. G. Hulten, J. Versalovic, and S. L. Kaplan, “Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005,” Journal of Clinical Microbiology, vol. 47, no. 6, pp. 1628–1630, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. H. S. Sader, P. R. Rhomberg, and R. N. Jones, “Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 3162–3165, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. J. M. Swenson, K. F. Anderson, D. R. Lonsway et al., “Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus,” Journal of Clinical Microbiology, vol. 47, no. 7, pp. 2013–2017, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. H. S. Sader, P. D. Fey, D. N. Fish et al., “Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4127–4132, 2009. View at Publisher · View at Google Scholar · View at PubMed
  21. M. J. Rybak, B. M. Lomaestro, J. C. Rotscahfer et al., “Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists,” Clinical Infectious Diseases, vol. 49, pp. 325–327, 2009. View at Google Scholar
  22. L. A. Mandell, R. G. Wunderink, A. Anzueto et al., “Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults,” Clinical Infectious Diseases, vol. 44, supplement 2, pp. S27–S72, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. A. R. Tunkel, B. J. Hartman, S. L. Kaplan et al., “Practice guidelines for the management of bacterial meningitis,” Clinical Infectious Diseases, vol. 39, no. 9, pp. 1267–1284, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. M. H. Scheetz, R. G. Wunderink, M. J. Postelnick, and G. A. Noskin, “Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia,” Pharmacotherapy, vol. 26, no. 4, pp. 539–550, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. D. W. King and M. A. Smith, “Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells,” Toxicology in Vitro, vol. 18, no. 6, pp. 797–803, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. I. Celik, M. Cihangiroglu, N. Ilhan, N. Akpolat, and H. H. Akbulut, “Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity,” Basic and Clinical Pharmacology and Toxicology, vol. 97, no. 5, pp. 325–332, 2005. View at Publisher · View at Google Scholar
  27. T. P. Lodise, B. Lomaestro, J. Graves, and G. L. Drusano, “Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1330–1336, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. M. M. Bergman, R. H. Glew, and T. H. Ebert, “Acute interstitial nephritis associated with vancomycin therapy,” Archives of Internal Medicine, vol. 148, no. 10, pp. 2139–2140, 1988. View at Google Scholar · View at Scopus
  29. C. E. Codding, L. Ramseyer, M. Allon, J. Pitha, and M. Rodriguez, “Tubulointerstitial nephritis due to vancomycin,” American Journal of Kidney Diseases, vol. 14, no. 6, pp. 512–515, 1989. View at Google Scholar · View at Scopus
  30. A. O. Wai, A. M. S. Lo, A. Abdo, and F. Marra, “Vancomycin-induced acute interstitial nephritis,” Annals of Pharmacotherapy, vol. 32, no. 11, pp. 1160–1164, 1998. View at Google Scholar · View at Scopus
  31. E. Fiaccadori, U. Maggiore, A. Arisi et al., “Outbreak of acute renal failure due to cefodizime-vancomycin association in a heart surgery unit,” Intensive Care Medicine, vol. 27, no. 11, pp. 1819–1822, 2001. View at Publisher · View at Google Scholar · View at PubMed
  32. H. Sokol, C. Vigneau, E. Maury, B. Guidet, and G. Offenstadt, “Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoside,” Nephrology Dialysis Transplantation, vol. 19, no. 7, pp. 1921–1922, 2004. View at Publisher · View at Google Scholar · View at PubMed